dusquetide

Small moleculeexperimental

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2013 (NCT02013050)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(N)=O)C(C)C
Mol. weight
553.71 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dusquetide
  • sgx942
  • sgx942

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06386744Phase 2Jul 31, 2024Soligenix
NCT03237325Phase 3Jul 25, 2017Soligenix
NCT02013050Phase 2Dec 1, 2013Soligenix
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SoligenixFor profit3322013
1 organizations
Page 1 / 1